![Kenneth Hillan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kenneth Hillan
Direktör/Styrelseledamot på
SANGAMO THERAPEUTICS, INC.
Förmögenhet: 5 378 $ per 2026-06-30
Profil
Kenneth J.
Hillan is currently an Independent Director at Sangamo Therapeutics, Inc. since 2020 and a Director at Zymeworks BC, Inc. since 2017.
Formerly, Dr. Hillan was CEO, Director & President-R&D Division at Achaogen, Inc. from 2017 to 2019; Independent Director at Relypsa, Inc. from 2015 to 2016; Independent Director at Zymeworks, Inc. from 2017 to 2024; SVP & Head-Roche Product Development, Asia Pacific at Genentech, Inc. from 2010 to 2011; Member of Roche Group from 1994 to 2011; Head-Therapeutics at 23andMe, Inc. from 2019 to 2021; and Chief Therapeutics Officer at Chrome Holding Co. from 2022 to 2023.
Dr. Hillan earned a doctorate from the University of Glasgow School of Medicine.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2025-06-12 | 99 600 ( 0,02 % ) | 5 378 $ | 2026-06-30 |
Aktiva positioner av Kenneth Hillan
| Företag | Position | Start |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2020-09-11 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Direktör/Styrelseledamot | 2017-02-03 |
Tidigare kända positioner av Kenneth Hillan
| Företag | Position | Slut |
|---|---|---|
| ZYMEWORKS INC. | Direktör/Styrelseledamot | 2024-02-08 |
| CHROME HOLDING CO. | Företagsledare/Principal | 2023-08-08 |
23andMe, Inc.
 23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Företagsledare/Principal | 2021-06-01 |
| ACHAOGEN | Verkställande Direktör | 2019-04-04 |
| RELYPSA INC | Direktör/Styrelseledamot | 2016-09-01 |
Kenneth Hillans utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
87
Första gradens relationer
10
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 10 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sangamo Therapeutics, Inc.
 Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops non-absorbed polymeric drugs for applications in cardiovascular and renal diseases | Health Technology |
University of Glasgow School of Medicine
 University of Glasgow School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
23andMe Holding Co.
 23andMe Holding Co. BiotechnologyHealth Technology Operates as a genetic testing company | Health Technology |
Zymeworks, Inc.
 Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
